Deerfield Partners

Deerfield Partners

Xconomy , MedCity News

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

MedCity News

bluebird bio's stock tanks after report of serious toxicity in sickle cell patient

$85,500,000 IPO
PE HUB

Xeris Pharmaceuticals goes public

Stock markets
$70,000,000 Post-IPO equity
PE HUB

Dicerna scores $70 mln

Funding Stock markets
$250,000,000 Post-IPO equity
Twitter

Boston Business on Twitter

$41,000,000 Venture capital (Series C)
Xconomy

Austin Biotech Xeris Names Edick CEO, Raises $41M in Series C Round

Health Funding
The Motley Fool

Better Buy: Agenus Inc. vs. bluebird bio

The Motley Fool

Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today

The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

bluebird bio Inc: Catnapping in Cambridge

The Motley Fool

Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys

The Motley Fool

bluebird bio, Inc. Takes Flight Towards First Approval

The Motley Fool

Here's Why bluebird bio.'s Stock Tumbled in March

The Motley Fool

Why bluebird bio's Stock Jumped 12.9% on Wednesday

The Motley Fool

Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals

The Motley Fool

Why Bluebird Bio Inc. Plunged Today

The Motley Fool

Why bluebird bio Inc Presented a Lower Price Today

The Motley Fool

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

Stock markets
The Motley Fool

Why bluebird bio Inc.'s Stock Dropped 34% in January

Stock markets